CN102070573A - Mono-tetrahydrofuran type sugar apple lactone compound with anti-tumor activity and application thereof - Google Patents
Mono-tetrahydrofuran type sugar apple lactone compound with anti-tumor activity and application thereof Download PDFInfo
- Publication number
- CN102070573A CN102070573A CN 201110047089 CN201110047089A CN102070573A CN 102070573 A CN102070573 A CN 102070573A CN 201110047089 CN201110047089 CN 201110047089 CN 201110047089 A CN201110047089 A CN 201110047089A CN 102070573 A CN102070573 A CN 102070573A
- Authority
- CN
- China
- Prior art keywords
- tumor activity
- thf
- cancer
- tetrahydrofuran
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a new mono-tetrahydrofuran type sugar apple lactone compound with anti-tumor activity, through systematic in-depth research of chemical ingredients of sugar apple seeds, the analysis of wave spectrum and mass spectrum data shows that the new mono-tetrahydrofuran type sugar apple lactone compound (Anno Shikemominbing) can be separated from the sugar apple seeds, in vivo and in vitro anti-tumor activity researches show that mono-tetrahydrofuran type sugar apple lactone provided by the invention has very strong anti-tumor activity for a variety of tumor cells, including lung cancer, breast cancer, liver cancer, cervical cancer and gastric cancer, and the toxicity test research shows that the mono-tetrahydrofuran type sugar apple lactone compound with the anti-tumor activity provided by the invention is expected to be developed into new anti-tumor medicaments.
Description
Technical field
The present invention relates to have the compound of anti-tumor activity, be specifically related to a kind of new single tetrahydrofuran (THF) type annonaceous acetogenins and purposes in prevention and treatment tumor disease thereof, belong to medical technical field with anti-tumor activity.
Background technology
Malignant tumour is the frequently-occurring disease and the common disease of serious harm human health and life, the Egyptian and existing record about tumour of China before 2000～3000 years.The a lot of countries that comprise China, especially medium-developed country, deadly due to the malignant tumour in all causes of death, account for first place or second, and sickness rate is worldwide still in rising trend, in the art treatment of tumour, radiotherapy, chemotherapy, biotherapy four big therapies, chemotherapy is still main methods of treatment, but well-known, existing chemotherapy medicine antitumor activity is limited, and toxic side effect is bigger, patient's tolerance is poor, and costs an arm and a leg.Therefore, generation and development by the chemical cancer-resisting substance preventing cancer in the research natural phant have become a key areas of cancer chemoprophylaxis research, and are subjected to the common concern and the research focus of countries in the world scientific circles.
Annona lactone is the class natural compounds that extraction separation obtains from the annonaceae plant, Annonaceousacetogenicompounds compounds has wide biological activity, most typical is desinsection and antitumor cell activity, studies show that Annona lactone has powerful cytotoxicity in vivo and in vitro, and kinds of tumor cells all shown biological activity preferably, the mechanism of action that studies show that the Annona lactone anti-tumor activity is by blocking-up DNA mitochondrial DNA NADH oxydo-reductase, thereby stop the transmission of respiratory chain electronics, suppress the generation of tumour cell ATP, make tumour cell because of hungry dead, its mechanism of action uniqueness, the mechanism of action that is different from general antitumor drug is called " star that tomorrow is anticancer ".
The waste that Sirikaya seed abandons after edible for sweetsop pulp, wherein Annonaceousacetogenicompounds compounds content is higher, in order to utilize this waste fully, it is turned waste into wealth, the present invention carries out system's further investigation to the Sirikaya seed chemical ingredients, separates obtaining a new single tetrahydrofuran (THF) type annonaceous acetogenins from Sirikaya seed.
Summary of the invention
Goal of the invention: the objective of the invention is in order to overcome the deficiencies in the prior art, a kind of new single tetrahydrofuran (THF) type annonaceous acetogenins and purposes in prevention and treatment tumor disease thereof with powerful antitumor activity is provided
Technical scheme: in order to realize above purpose, the technical scheme that the present invention takes is:
Have single tetrahydrofuran (THF) type Annonaceousacetogenicompounds compounds of anti-tumor activity, its structural formula is as follows:
Molecular formula is C
35H
64O
5, the structure end has α, and β-γ unsaturated lactone ring has a single tetrahydrofuran (THF) ring in the molecular chain, and with its called after An Nuoshikemomin third.
Extraction and separation method with single tetrahydrofuran (THF) type annonaceous acetogenins of anti-tumor activity provided by the invention may further comprise the steps:
A, get Sirikaya seed and pulverize the back solvent extraction, the recovery extracting solution obtains concentrated solution;
B, with concentrated solution through the normal-phase chromatography chromatographic separation, obtain target compound An Nuoshikemomin third.
Among the above preparation method, the used extraction solvent of step a can be the mixed solvent of one of them or they such as sherwood oil, chloroform, ethyl acetate, preferred chloroform; Extracting method can be cold soaking, diacolation, microwave extraction or supersound extraction, preferred diacolation and supersound extraction.
Among the above preparation method, step b extracting solution can pass through chromatography after concentrating, used chromatography parting material can be a silica gel, aluminum oxide, contain cyano group or amino silane group silica gel, wherein preferred silica gel, used eluting solvent is sherwood oil and ethyl acetate, collecting the elutriant that contains target compound respectively concentrates, refined liquid after concentrating respectively can be at silica gel, aluminum oxide, contain in cyano group or the amino materials such as silane group silica gel and carry out chromatographic separation, sherwood oil and ethyl acetate gradient elution, collect elutriant, the elutriant recrystallization obtains new single tetrahydrofuran (THF) type Annona lactone An Nuoshikemomin third respectively.
Single tetrahydrofuran (THF) type annonaceous acetogenins with anti-tumor activity provided by the invention becomes formulations such as tablet, capsule, injection, powder injection, granule, lipomul, micro-capsule, dripping pill, ointment or skin-permeable and control-released plaster with single tetrahydrofuran (THF) type Annonaceousacetogenicompounds compounds (An Nuoshikemomin third) with pharmaceutically acceptable preparing carriers.
When single tetrahydrofuran (THF) type Annona lactone provided by the invention is made tablet,, add magnesium stearate lubricant when needing, mix single tetrahydrofuran (THF) type Annona lactone and lactose or W-Gum, whole grain, compressing tablet is made tablet then.
When single tetrahydrofuran (THF) type Annona lactone provided by the invention is made capsule single tetrahydrofuran (THF) type Annona lactone and carrier lactose or W-Gum are mixed whole grain, the encapsulated then capsule of making.
When single tetrahydrofuran (THF) type Annona lactone provided by the invention is made granule, single tetrahydrofuran (THF) type Annona lactone and thinner lactose or W-Gum, mix, whole grain, drying is made granule.
When single tetrahydrofuran (THF) type Annona lactone provided by the invention was made powder injection, the lyophilize of single tetrahydrofuran (THF) type Annona lactone, powder injection was made in sterilization.
When single tetrahydrofuran (THF) type Annona lactone provided by the invention is made injection liquid, get single tetrahydrofuran (THF) type Annona lactone adding physiological saline solution and add activated carbon then, stir, 80 ℃ were heated 30 minutes, filter, regulate the pH value, be filtered to clear and bright with sintered glass funnel or other filter, can was made injection liquid in 30 minutes 100 to 115 ℃ of sterilizations.
Adding carrier when single tetrahydrofuran (THF) type Annona lactone provided by the invention is made formulation such as lipomul, ointment or skin-permeable and control-released plaster prepares by the pharmacy ordinary method.
The application of single tetrahydrofuran (THF) type Annonaceousacetogenicompounds compounds (An Nuoshikemomin third) with anti-tumor activity provided by the invention in the preparation antitumor drug.
As preferred version, the application of single tetrahydrofuran (THF) type Annonaceousacetogenicompounds compounds in the preparation antitumor drug with anti-tumor activity provided by the invention, described tumour is lung cancer, mammary cancer, liver cancer, cervical cancer and cancer of the stomach.
Beneficial effect: the single tetrahydrofuran (THF) type Annonaceousacetogenicompounds compounds with anti-tumor activity provided by the invention is compared with prior art and is had the following advantages:
The present invention is by carrying out system's further investigation to the Sirikaya seed chemical ingredients, show from Sirikaya seed, to separate with MASS SPECTRAL DATA ANALYSIS and obtain a single tetrahydrofuran (THF) type Annonaceousacetogenicompounds compounds (An Nuoshikemomin third) through wave spectrum, be new compound.And through studies show that with anti tumor activity in vitro in the body, single tetrahydrofuran (THF) type Annona lactone provided by the invention is to kinds of tumor cells, comprise lung cancer, mammary cancer, liver cancer, cervical cancer and cancer of the stomach all have very strong anti-tumor activity, and studies show that the single tetrahydrofuran (THF) type Annonaceousacetogenicompounds compounds toxicity with anti-tumor activity provided by the invention is lower, is a kind of good antineoplastic novel compound through toxicity test.
Description of drawings
Fig. 1 is the structural representation of An Nuoshikemomin third;
Fig. 2 is the high resolution mass spectrum figure of An Nuoshikemomin third;
Fig. 3 is An Nuoshikemomin's third
1H NMR figure;
Fig. 4 is An Nuoshikemomin's third
13C NMR figure.
Embodiment
According to following embodiment, the present invention may be better understood.Yet, those skilled in the art will readily understand that the described concrete material proportion of embodiment, processing condition and result thereof only are used to illustrate the present invention, and should also can not limit the present invention described in detail in claims.
The preparation of embodiment 1 single tetrahydrofuran (THF) type Annonaceousacetogenicompounds compounds (An Nuoshikemomin third)
Get 10 kilograms of dry Sirikaya seeds, pulverize back chloroform diacolation, reclaim and merge percolate, filter, filtrate decompression reclaims and obtains 1 kilogram of concentrated solution, concentrated solution carries out column chromatography for separation with purification on normal-phase silica gel, with petroleum ether-ethyl acetate-methyl alcohol gradient elution, collect 400 parts of cuts altogether, be merged into five parts (F1 ~ F5) gets the F2(63 gram) according to the thin-layer chromatography situation and carry out column chromatography for separation, with the petroleum ether-ethyl acetate (gradient elution of 20:1 ~ 0:1) through purification on normal-phase silica gel, be divided into 8 parts (F6 ~ F13) according to the thin-layer chromatography situation, get F9 amalgamation liquid precipitate through the petroleum ether-ethyl acetate recrystallization, obtain compound An Nuoshikemomin the third, structural formula as shown in Figure 1, detect through high performance liquid phase, purity is 99.1%.
The structure elucidation of An Nuoshikemomin third: white powder, molecular formula: C
35H
64O
5Fusing point: 64-65 ° C; Specific rotation: [α]
25 D+ 12.8 (
c0.10, MeOH); Ultraviolet: (MeOH)
λ Max(log
ε) 218 (3.71) nm; Infrared: IR (KBr)
ν Max3424,2918,2852,1743 and 1070 cm
-1 1H NMR and
13C NMR data see Table 1, Fig. 3 and 4; High resolution electrospray ionization mass spectrum (HRESIMS) as Fig. 2: quasi-molecular ion peak
M/z[565.4808 M+H]
+(calculated value 585.4832) and
M/z[587.4665 M+Na]
+(calculated value 587.4651).Determine that in conjunction with ultimate analysis relative molecular weight is 580, determine that molecular formula is C
35H
64O
5, compound UV λ
Max=215 nm and keed reagent react are red-purple, and α has been described, the existence of β-γ unsaturated lactone ring.Its
1δ among the H-NMR
H6.97 (H-33), 4.99 (H-34), 1.39 (H-35) and
13δ among the C-NMR
C173.54 (C-1), 134.02 (C-2), 148.49 (C-33), 77.05 (C-34), 18.88 (C-35), these are characteristic signals of α, β-γ unsaturated lactone ring;
1δ among the H-NMR
H2.26 the triplet of locating shows that the C-4 position does not have oxy radical to replace,
1δ 3.38 (H-11) among the H-NMR, δ 3.89 (H-16), 3.83 (H-12,15) and
13C-NMR δ 74.01 (C-11), 82.90 (C-12/15), 81.83 (C-12/15), the peak of 71.24 (C-16) shows that existence that single tetrahydrofuran (THF) ring is arranged in the structure and the both sides of THF respectively have a hydroxyl adjacent, because its δ
C74.01 (C-11), 71.24 (C-16); δ
H3.38 (H-11), δ 3.89 (H-16) is so be respectively erythro form and Su Shi.The position of substitution of inferring THF according to ESI-MS/MS data (m/z=209,221,289,303,317,307,237) is between C-11 and the C-16.The NMR data of binding compounds Annonacin A and Reticulatain-1 infer that its relative configuration is th/t/er, are Annonacin A hypotype.In sum, in conjunction with various physics and chemistry and spectral data, be accredited as the new ring-like sweetsop branch of a single tetrahydrofuran (THF) lactone compound, called after An Nuoshikemomin third, cycle chemistry is by name: (S)-3-((R)-9-hydroxyl-9-((2R, 5R)-5-((S)-1-hydroxyl heptadecyl)-2-tetrahydrofuran base) nonyl)-5-methyl furan-2 (5H)-ketone.
(solvent is CDCl to the NMR data of table 1. An Nuoshikemomin third compound
3, test be 300MHz)
The acute toxicity test of embodiment 2 An Nuoshikemomin third
Press the Bliss method and calculate mouse medium lethal dose LD
50Value, measurement result is as shown in table 2:
The acute toxicity test data of table 2 An Nuoshikemomin third
By table 2 experiment gained LD
50Value illustrates that the acute toxicity of compound An Nuoshikemomin third provided by the invention is lower, the toxicity minimum of compound An Nuoshikemomin third oral administration in the route of administration.
The embodiment 3 An Nuoshikemomin third external restraining effect to human tumor cells
With people's lung cancer (MCF-7), mammary cancer (A-5408), people's liver cancer (SMMC-7451), human cervical carcinoma (Hela) and 5 kinds of knurl strains of people's cancer of the stomach (SGC-7901), adopt tetrazolium bromide reduction method (MTT) to carry out anticancer experiment in vitro, compound An Nuoshikemomin third establishes 5 concentration, with the positive control group of taxol (Taxol), is the negative control group of methyl-sulphoxide with the solvent of sample.Used mouse is cleaning level kunming mice.By the experimental result of the table 3 different restraining effect of demonstration of third pair 5 strain human tumor cells of compound An Nuoshikemomin as can be seen, the anticancer experiment in vitro data show that compound An Nuoshikemomin third provided by the invention has shown very strong anti-tumor activity, wherein lung cancer (MCF-7) tumour cell are compared with the positive drug taxol to have stronger tumour cell selection inhibition activity.
Table 3 An Nuoshikemomin third and taxol are to the restraining effect of 5 strain tumour cells
The restraining effect of in embodiment 4 compound An Nuoshikemomin third body mouse transplantability hepatoma Heps being produced
Carry out the inhibition experiment that mouse interior tumor is produced with mouse transplantability hepatoma Heps, compound An Nuoshikemomin third establishes 3 dosage groups, promptly high, medium and low 3 groups, with the positive control group of taxol, solvent with sample is the negative control group of soybean oil, establishes 10 mouse for every group, every group of mouse peritoneal injection every day 0.2ml, continuous 7 days, put to death mouse in the 8th day, get tumour, weigh, calculate tumour inhibiting rate, concrete experimental result is shown in Table 4.
Table 4 compound An Nuoshikemomin third intraperitoneal administration is to the inhibition experimental result of rat liver cancer HepS
Ratio of outflow (%)=(1-medicine group knurl weight/feminine gender group knurl is heavy) * 100% * gives the solution with the same amount sample dissolution, down together.
Draw the show strong inhibition activity of third pair of mouse hepatoma of compound An Nuoshikemomin Heps growth by experimental result table 4, the height of An Nuoshikemomin third, middle concentration all have statistical significance with respect to the feminine gender group, wherein the high density group of An Nuoshikemomin third is 58.7% to mouse hepatoma Heps inhibiting rate, demonstrates good antitumor activity.
With murine sarcoma S
180Carry out the inhibition experiment that mouse interior tumor is produced, compound An Nuoshikemomin third respectively establishes 3 dosage groups, and promptly high, medium and low 3 groups, with the positive control group of taxol, solvent with sample is the negative control group of soybean oil, establish 10 mouse for every group, every group of mouse peritoneal injection every day 0.2ml, continuous 7 days, put to death mouse in the 8th day, get tumour, weigh, calculate tumour inhibiting rate. the results are shown in Table 5.
Table 5 compound An Nuoshikemomin third intraperitoneal administration is to the inhibition experimental result of mouse meat cancer S180
Tumour inhibiting rate (%)=(1-medicine group knurl weight/feminine gender group knurl is heavy) * 100% * gives the solution with the same amount sample dissolution, down together.
Draw third pair of Mouse Liver sarcoma of compound An Nuoshikemomin S by experimental result table 5
180Also show stronger inhibition activity, with respect to the height of feminine gender group compound, middle concentration group all has statistical significance, and the high density group of An Nuoshikemomin third is to murine sarcoma S
180Inhibiting rate is 57.8%, demonstrates than taxol to have better antitumor activity.The experiment of above anti-tumor in vivo shows that further the ring-like sweetsop branch of single tetrahydrofuran (THF) provided by the invention lactone compound has high anti-tumor activity, low toxic side effect, and being expected to develop becomes new antitumor drug.
The preparation of embodiment 6 tablets
Get above-mentioned An Nuoshikemomin third and add medicinal supplementary product starch, Magnesium Stearate etc. in right amount, fully behind the mixing, compressing tablet is made every tablet of tablet that contains the above-mentioned An Nuoshikemomin third of 1mg and is orally used.
The preparation of embodiment 7 capsules
Getting above-mentioned An Nuoshikemomin third, to add medicinal supplementary product starch an amount of, fully behind the mixing, incapsulates, and makes every capsule that contains the above-mentioned An Nuoshikemomin third of 1mg and orally use.
The preparation of embodiment 8 micro-capsules
It is an amount of to get gummi arabicum pulveratum, above-mentioned An Nuoshikemomin third is got in adding, distilled water is made colostrum in right amount, and make emulsion in right amount with 3% Arabic glue, emulsion is heated to 45, and to add 3% gelatin solution when spending an amount of and with 10% acetate solution accent pH4.1 ~ 4.3, add distilled water, 3% formaldehyde is an amount of, stir to make it solidify setting, with 5% sodium hydroxide accent pH7.0 ~ 7.5, it is an amount of to add 10% starch at last, makes the micro-capsule that every gram contains 1mg An Nuoshikemomin third.
Above embodiment only is explanation technical conceive of the present invention and characteristics; its purpose is to allow the people that is familiar with this technology understand content of the present invention and is implemented; can not limit protection scope of the present invention with this; all equivalences that spirit is done according to the present invention change or modify, and all should be encompassed in protection scope of the present invention.
Claims (4)
1. single tetrahydrofuran (THF) type annonaceous acetogenins with anti-tumor activity is characterized in that its structural formula is as follows:
。
2. the single tetrahydrofuran (THF) type annonaceous acetogenins with anti-tumor activity according to claim 1, it is characterized in that, single tetrahydrofuran (THF) type annonaceous acetogenins is become the medicine of tablet, capsule, injection, powder injection, granule, lipomul, micro-capsule, dripping pill, ointment or skin-permeable and control-released plaster formulation with pharmaceutically acceptable preparing carriers.
3. the described application of single tetrahydrofuran (THF) type annonaceous acetogenins in the preparation antitumor drug of claim 1 with anti-tumor activity.
4. according to the application of the single tetrahydrofuran (THF) type annonaceous acetogenins shown in the claim 3 in the preparation antitumor drug, it is characterized in that described tumour is lung cancer, mammary cancer, liver cancer, cervical cancer and cancer of the stomach with anti-tumor activity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100470893A CN102070573B (en) | 2011-02-28 | 2011-02-28 | Mono-tetrahydrofuran type sugar apple lactone compound with anti-tumor activity and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100470893A CN102070573B (en) | 2011-02-28 | 2011-02-28 | Mono-tetrahydrofuran type sugar apple lactone compound with anti-tumor activity and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102070573A true CN102070573A (en) | 2011-05-25 |
| CN102070573B CN102070573B (en) | 2012-06-20 |
Family
ID=44029354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100470893A Expired - Fee Related CN102070573B (en) | 2011-02-28 | 2011-02-28 | Mono-tetrahydrofuran type sugar apple lactone compound with anti-tumor activity and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102070573B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309516A (en) * | 2016-11-02 | 2017-01-11 | 南京中医药大学 | Sweetsop peel volatile oil extract with anti-tumor activity as well as preparation method and application thereof |
| CN107007826A (en) * | 2017-04-19 | 2017-08-04 | 南京中医药大学 | Radix Isatidis activated protein and preparation method and application |
| CN107674065A (en) * | 2017-10-13 | 2018-02-09 | 江苏建康职业学院 | Annonaceous acetogenins and its application with antitumor activity |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1861597A (en) * | 2006-06-16 | 2006-11-15 | 南京中医药大学 | Internal ester monomer compound and its application in preparing anti cancer medicine |
| CN1869031A (en) * | 2006-06-30 | 2006-11-29 | 南京中医药大学 | Lactone monomer compound and its application in preparing anticancer medicine |
| CN101108840A (en) * | 2007-07-06 | 2008-01-23 | 中国科学院上海有机化学研究所 | Chirality anona squamosa L. lactone compound with conformation limitation structure and synthesizing method and use thereof |
-
2011
- 2011-02-28 CN CN2011100470893A patent/CN102070573B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1861597A (en) * | 2006-06-16 | 2006-11-15 | 南京中医药大学 | Internal ester monomer compound and its application in preparing anti cancer medicine |
| CN1869031A (en) * | 2006-06-30 | 2006-11-29 | 南京中医药大学 | Lactone monomer compound and its application in preparing anticancer medicine |
| CN101108840A (en) * | 2007-07-06 | 2008-01-23 | 中国科学院上海有机化学研究所 | Chirality anona squamosa L. lactone compound with conformation limitation structure and synthesizing method and use thereof |
Non-Patent Citations (2)
| Title |
|---|
| 《J. Med. Chem.》 20030621 Yuka Nakanishi et al. Acetogenins as Selective Inhibitors of the Human Ovarian 1A9 Tumor Cell Line 3185-3188 1-4 第46卷, 第15期 * |
| 《J. Nat. Prod.》 20010707 Fang rongchang et al. Novel Cytotoxic Annonaceous Acetogenins from Annona muricata 925-931 1-4 第64卷, 第7期 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309516A (en) * | 2016-11-02 | 2017-01-11 | 南京中医药大学 | Sweetsop peel volatile oil extract with anti-tumor activity as well as preparation method and application thereof |
| CN106309516B (en) * | 2016-11-02 | 2020-02-21 | 南京中医药大学 | Annona squamosa pericarp volatile oil extract with anti-tumor activity and preparation method and application thereof |
| CN107007826A (en) * | 2017-04-19 | 2017-08-04 | 南京中医药大学 | Radix Isatidis activated protein and preparation method and application |
| CN107007826B (en) * | 2017-04-19 | 2020-03-31 | 南京中医药大学 | Active protein of isatis root and its preparing process and application |
| CN107674065A (en) * | 2017-10-13 | 2018-02-09 | 江苏建康职业学院 | Annonaceous acetogenins and its application with antitumor activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102070573B (en) | 2012-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104341430B (en) | A kind of soil Radix Glycyrrhizae A and extracting method thereof and purposes | |
| CN102516344B (en) | Compound with antitumor activity and preparation method and application thereof | |
| CN102070573B (en) | Mono-tetrahydrofuran type sugar apple lactone compound with anti-tumor activity and application thereof | |
| CN102133220B (en) | Preparation method of pulsatilla saponin A | |
| CN1312253A (en) | Radde anemone rhizome extract and its prepn process and use | |
| CN106631804A (en) | Compound separated out from labiatae isodon plant, and preparation method and application thereof | |
| CN106749124B (en) | Neighbour's double tetrahydrofuran type Annonaceousacetogenicompounds compounds with anti-tumor activity and the preparation method and application thereof | |
| CN102731276A (en) | Diterpene compound possessing antitumor activity, preparation method thereof and application thereof | |
| CN106543117B (en) | With anti-tumor activity double tetrahydrofuran type Annonaceousacetogenicompounds compounds and the preparation method and application thereof | |
| CN107840836A (en) | Icariine K and preparation method thereof and the application on medicine | |
| CN102908340B (en) | Isolicoflavonol-containing antitumor drug and application thereof | |
| CN102153529B (en) | Single-tetrahydrofuran-type annonaceous acetogenin compounds with antitumor activity and application thereof | |
| CN107266516B (en) | Triterpenoid with anti-tumor activity and the preparation method and application thereof | |
| CN113480590B (en) | Wilforinupinone, its preparation method and application in medicine | |
| CN106543159B (en) | Epoxy type Annonaceousacetogenicompounds compounds with anti-tumor activity and the preparation method and application thereof | |
| CN103833823A (en) | Diterpene dimer compounds and pharmaceutical compositions and preparation method and application thereof | |
| CN109111462B (en) | Salvianolide, preparation method thereof and medicine containing same | |
| CN107674065A (en) | Annonaceous acetogenins and its application with antitumor activity | |
| CN113321631B (en) | Biandrographolide G, preparation method and application thereof in medicines | |
| CN105541858A (en) | Xanthone compositions, and preparation method, compositions and application thereof | |
| CN101735189A (en) | Preparation method, preparation and application of tricin | |
| CN105541631B (en) | Raw element A (spiratisanin A) of meadow sweet Ah Ti and preparation method thereof and the application on medicine | |
| CN104257641B (en) | A kind of C36Polyacetylene compound and preparation thereof and application | |
| CN1188118C (en) | Medicine for preventing or treating cancer and its usage | |
| CN109705183A (en) | Smelly seven secondary metabolites and its pharmaceutical composition and preparation method and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120620 Termination date: 20150228 |
|
| EXPY | Termination of patent right or utility model |